Targeting mitochondrial dysfunction in neurodegeneration: challenges and opportunities for disease-modifying pharmacology

Mitochondria in Neuronal Health: Why Neurons Are Uniquely Vulnerable

The neuronal world resembles a vast, living transport network: highways of axons, branching side streets of dendrites, crowded junctions of synapses, and finely tuned regulatory stoplights that control electrical flow. Within this landscape, energy is the currency that keeps traffic moving. Neurons are among the most metabolically demanding cells in the body; required to sustain action potentials, recycle synaptic vesicles, and transport cargo over distances that can span a metre or more. Among all cellular organelles, mitochondria therefore occupy a uniquely central position, integrating ATP production, calcium buffering, redox control, and apoptotic signalling.

The brain consumes a disproportionate share of the body’s energy budget, with neurons relying heavily on oxidative phosphorylation to maintain ion gradients and support rapid electrical activity¹. At synapses, growth cones, and nodes of Ranvier, ATP is required locally for vesicle cycling, cytoskeletal remodelling, and neurotransmission, making precise mitochondrial positioning essential². When this finely tuned energy supply falters, synaptic transmission weakens, and neuronal excitability becomes unstable³.

Neuronal vulnerability is further amplified by extreme cellular geometry. Biosynthesis is concentrated in the soma, yet most functional demand lies far away, in distant axon terminals and dendritic spines. Mitochondria must therefore be actively transported along microtubule “railways” by motor proteins and docked at sites of high metabolic demand. Disruption of this trafficking or anchoring compromises local ATP availability and calcium buffering, undermining synaptic integrity and predisposing neurons to degeneration⁴. In this way, mitochondrial failure strikes at the very infrastructure that sustains long-range communication in the nervous system.

Figure 1: Illustrates the network of the axon transporting signalling endosomes retrograde using dynein transporters and anterograde transport using kinesin proteins. Created in BioRender.com 

Hallmarks of Mitochondrial Dysfunction in Neurodegeneration

Despite distinct initiating triggers, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease converge on a common pathological hub: mitochondrial dysfunction⁵. When a central feature is impaired oxidative phosphorylation, this leads to ATP depletion and energetic collapse in the most vulnerable neuronal populations⁵˒⁶. This bioenergetic failure is accompanied by excessive generation of reactive oxygen species (ROS), which damage proteins, lipids, and nucleic acids, further destabilising the respiratory chain and amplifying oxidative stress⁶.

Mitochondrial DNA (mtDNA) is particularly susceptible to injury. With limited repair capacity and constant exposure to ROS, mtDNA mutations accumulate with age and disease, disrupting the expression of essential electron-transport-chain subunits and reinforcing a vicious cycle of respiratory dysfunction and oxidative damage⁷˒⁸. As ETC efficiency declines, ROS production rises, feeding forward into progressive mitochondrial failure⁶.

At the network level, disturbances in mitochondrial dynamics further erode neuronal resilience. Balanced cycles of fission and fusion are required to maintain mitochondrial quality, distribution, and functional complementation. In neurodegeneration, this balance is lost: excessive fragmentation or hyperfusion distorts mitochondrial architecture and impairs delivery to synapses⁹. Compounding this, defective mitophagy prevents efficient clearance of damaged organelles, allowing dysfunctional mitochondria to persist and propagate stress signals throughout the neuron⁵˒⁷.

Mitochondria also act as critical buffers of synaptic calcium. During neuronal firing, rapid calcium influx must be tightly controlled to prevent excitotoxicity. When mitochondrial calcium handling is compromised, cytosolic calcium overload triggers aberrant signalling cascades and cell death pathways¹⁰. Together, impaired bioenergetics, oxidative stress, mtDNA damage, altered dynamics, defective mitophagy, and calcium dysregulation define a conserved mitochondrial signature across neurodegenerative disorders, positioning mitochondrial failure as a primary driver rather than a secondary by-product of disease.

Therapeutic and Policy Implications: Mitochondrial Targets

From a pharmacological perspective, mitochondria represent both an alluring and formidable target. They sit at the crossroads of energy metabolism, redox homeostasis, calcium signalling, and apoptosis, making them attractive nodes for disease-modifying intervention¹¹˒¹². Yet this same centrality renders them difficult to manipulate without off-target toxicity.

Antioxidant strategies have long been pursued and have shown robust neuroprotection in preclinical models. However, clinical translation has been disappointing, likely reflecting poor blood–brain-barrier penetration, inadequate mitochondrial targeting, and treatment initiated after irreversible neuronal loss has already occurred¹³˒¹⁴. These failures underscore the need for approaches that move beyond global ROS scavenging toward restoration of mitochondrial quality control.

Emerging therapies aim to enhance mitophagy and mitochondrial turnover¹⁵˒¹⁶, rebalance fission–fusion dynamics¹¹˒¹⁶, and stimulate mitochondrial biogenesis through metabolic signalling pathways⁵˒¹⁷. Additional strategies seek to stabilise neuronal bioenergetics or improve calcium handling at synapses¹². Collectively, these approaches reflect a shift from symptomatic relief toward correcting the underlying bioenergetic and homeostatic defects that precede overt neurodegeneration.

A major barrier to translation remains the lack of robust in vivo biomarkers of mitochondrial dysfunction. Without reliable imaging probes, fluid biomarkers, or functional readouts, it is difficult to identify patients in early stages when mitochondrial rescue might still alter disease trajectory. From a policy perspective, this highlights the need to prioritise early-stage and preventive neurodegeneration research, alongside sustained investment in translational mitochondrial biology¹⁸˒¹⁹.

Key priorities include the development of mitochondrial imaging tools, circulating biomarkers of bioenergetic stress, and adaptive clinical trial designs centred on mitochondrial endpoints. Longitudinal cohorts and early intervention studies will be essential to test whether targeting mitochondrial failure can truly modify disease course rather than merely slow terminal decline²⁰.

In the crowded cityscape of the degenerating brain, mitochondria function as power stations, traffic controllers, and emergency response units all at once. Preserving their integrity may therefore be one of the most promising routes toward disease-modifying therapies, transforming neurodegeneration from an inevitable blackout into a condition whose progression can be meaningfully delayed, or even prevented.

References

1. Xavier J, Rodrigues CM, Solá S. Mitochondria: major regulators of neural development. Neuroscientist. 2016;22(4):346-358. doi:10.1177/1073858415585472
2. Pekkurnaz G, Wang X. Mitochondrial heterogeneity and homeostasis through the lens of a neuron. Nat Metab. 2022;4(7):802-812. doi:10.1038/s42255-022-00594-w
3. Mahadevan V, Khademullah CS, Dargaei Z, Chevrier J, Uvarov P, Kwan J, et al. Bioenergetic regulation of neuronal excitability and synaptic function by mitochondria. J Neurosci. 2021;41(30):6503-6521. doi:10.1523/JNEUROSCI.2976-20.2021
4. Misgeld T, Schwarz TL. Mitostasis in neurons: maintaining mitochondria in an extended cellular architecture. Neuron. 2017;96(3):651-666. doi:10.1016/j.neuron.2017.09.055
5. Yang H. Mitochondrial dysfunction in neurodegenerative diseases. Cells. 2025;14(4):276. doi:10.3390/cells14040276
6. Wen P, Sun Z, Gou F, Wang J, Fan Q, Zhao D, Yang L. Oxidative stress and mitochondrial impairment: key drivers in neurodegenerative disorders. Ageing Res Rev. 2025;104:102667. doi:10.1016/j.arr.2025.102667
7. Shang D, Huang M, Wang B, Yan X, Wu Z, Zhang X. mtDNA maintenance and alterations in the pathogenesis of neurodegenerative diseases. Curr Neuropharmacol. 2023;21(3):578-598. doi:10.2174/1570159X20666220810114644
8. Bazzani V, Redin M, McHale J, Perrone L, Vascotto C. Mitochondrial DNA repair in neurodegenerative diseases and ageing. Int J Mol Sci. 2022;23(19):11391. doi:10.3390/ijms231911391
9. Guan D, Liang C, Zheng D, Liu S, Luo J, Cai Z, Zhang H, Chen J. The role of mitochondrial remodelling in neurodegenerative diseases. Neurochem Int. 2025;183:105927. doi:10.1016/j.neuint.2024.105927
10. Cai Q, Jeong YY. Mitophagy in Alzheimer’s disease and other age-related neurodegenerative diseases. Cells. 2020;9(1):150. doi:10.3390/cells9010150
11. Choi E, Kim M, Park S. Targeting mitochondrial dysfunction and reactive oxygen species for neurodegenerative disease treatment. Int J Mol Sci. 2024;25(14):7952. doi:10.3390/ijms25147952
12. Plascencia-Villa G, Perry G. Exploring molecular targets for mitochondrial therapies in neurodegenerative diseases. Int J Mol Sci. 2023;24(15):12486. doi:10.3390/ijms241512486
13. Fields M, Marcuzzi A, Gonelli A, Celeghini C, Maximova N, Rimondi E. Mitochondria-targeted antioxidants, an innovative class of antioxidant compounds for neurodegenerative diseases: perspectives and limitations. Int J Mol Sci. 2023;24(4):3739. doi:10.3390/ijms24043739
14. Morén C, de Souza R, Giraldo D, Uff C. Antioxidant therapeutic strategies in neurodegenerative diseases. Int J Mol Sci. 2022;23(16):9328. doi:10.3390/ijms23169328
15. Antico O, Thompson P, Hertz NT, Muqit MMK, Parton LE. Targeting mitophagy in neurodegenerative diseases. Nat Rev Drug Discov. 2025;24(4):276-299. doi:10.1038/s41573-024-01105-0
16. Zhou M, Zheng M, Liang S, Li M, Zhang S, Song X, Hu Y, Lyu Y, Ou X, Yue C. Inherent potential of mitochondria-targeted interventions for chronic neurodegenerative diseases. Neural Regen Res. 2026;21(10):1409-1427. doi:10.4103/nrr.nrr-d-24-01507
17. Trushina E, Nguyen T, Trushin S. Modulation of mitochondrial function as a therapeutic strategy for neurodegenerative diseases. J Prev Alzheimers Dis. 2023;10(4):675-685. doi:10.14283/jpad.2023.108
18. Meng K, Jia H, Hou X, Zhu Z, Lu Y, Feng Y, Feng J, Xia Y, Tan R, Cui F, Yuan J. Mitochondrial dysfunction in neurodegenerative diseases: mechanisms and corresponding therapeutic strategies. Biomedicines. 2025;13(2):327. doi:10.3390/biomedicines13020327
19. Connolly NMC, Theurey P, Ádám-Vizi V, Bazan NG, Bernardi P, Bolaños JP, et al. Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases. Cell Death Differ. 2018;25(3):542-572. doi:10.1038/s41418-017-0020-4
20. Klemmensen ÅK, Borrowman S, Pearce C, Pyles B, Chandra B. Early biomarkers and longitudinal cohort strategies for neurodegenerative disease prevention. Neurotherapeutics. 2023;21(1):1-21. doi:10.1016/j.neurot.2023.10.002